2 months Is Pfizer’s Stock Overvalued Or Undervalued? Benzinga    

Pfizer Inc. (NYSE: PFE) shares have lagged the S&P 500 in 2021, generating a year-to-date total return of 16.6%.

Pfizer has gotten plenty of headlines for its COVID-19 vaccine, but investors may be wondering just how much value is left in the pharma giant’s stock?

Earnings: A price-to-earnings ratio (PE) is one of the most basic fundamental metrics for gauging a stock’s value. The lower the PE, the higher the value. For comparison, the S&P 500’s PE is currently at about 34, more than double its long-term average of 15.9.

Pfizer’s PE is currently 19, significantly below the S&P 500 average as a whole. Pfizer's PE ratio is down 41.7% over the past …

Full story available on Benzinga.com

Read full article Is Pfizer’s Stock Overvalued Or Undervalued? and don't miss , , and other topics, financial news headlines, business stories, opinions and trade analysis on Market Insider.

· ·